VACC · Vaccitech PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | - | - | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.59M | - | $5.39M | $7.95M | $8.29M | - | $11.14M | $11.66M | $11.13M | - |
| SG&A | $2.53M | - | $5.17M | $15.38M | $12.64M | - | $961.0K | $7.20M | $5.99M | - |
| Total Operating Expenses | $6.12M | - | $15.22M | $23.34M | $20.93M | - | $24.56M | $18.86M | $17.12M | - |
| D&A | $856.0K | - | $100.0K | $1.20M | $2.03M | - | $700.0K | $700.0K | $1.43M | - |
| Operating Income | ($6.08M) | - | ($15.07M) | ($23.32M) | ($20.60M) | - | ($9.38M) | ($18.29M) | ($16.91M) | - |
| Interest Expense | $13.0K | - | $13.0K | $12.0K | $12.0K | - | $17.0K | $14.0K | $12.0K | - |
| Income Tax | ($16.0K) | - | ($71.0K) | ($25.0K) | ($22.0K) | - | ($3.0K) | ($7.0K) | ($37.0K) | - |
| Net Income | ($5.53M) | - | ($14.57M) | ($21.12M) | ($19.65M) | - | ($8.11M) | ($16.93M) | ($15.49M) | - |
| EPS - Basic | ($0.14) | - | ($0.36) | ($0.52) | ($0.49) | - | ($0.21) | ($0.43) | ($0.40) | - |
| EPS - Diluted | ($0.14) | - | ($0.36) | ($0.52) | ($0.49) | - | ($0.21) | ($0.43) | ($0.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.86M | $70.46M | $74.27M | $86.26M | $99.12M | $110.66M | $106.10M | $117.77M | $129.97M | $142.09M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $993.0K | $350.0K | $698.0K | $1.80M | $1.36M | $2.47M | $3.08M | $2.56M | $1.16M | $1.60M |
| Current Assets | $72.66M | $77.79M | $86.78M | $100.41M | $109.88M | $125.74M | $134.65M | $131.88M | $143.13M | $156.91M |
| Total Assets | $92.14M | $98.17M | $109.20M | $129.56M | $142.00M | $160.33M | $188.69M | $186.75M | $199.48M | $214.51M |
| Current Liabilities | $12.00M | $10.02M | $10.80M | $12.72M | $11.98M | $15.66M | $15.07M | $15.59M | $12.84M | $12.60M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $25.66M | $23.88M | $24.64M | $27.08M | $26.40M | $30.19M | $29.23M | $29.96M | $27.47M | $27.51M |
| Stockholders' Equity | $66.40M | $74.21M | $84.47M | $102.38M | $115.49M | $130.03M | $159.29M | $156.62M | $171.83M | $186.78M |
| Retained Earnings | ($309.63M) | ($304.09M) | ($293.00M) | ($278.44M) | ($257.31M) | ($237.66M) | ($217.12M) | ($209.01M) | ($192.08M) | ($176.59M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.37M) | - | - | - | ($14.90M) | - | - | - | ($11.82M) | - |
| Investing Cash Flow | $55.0K | - | - | - | ($5.0K) | - | - | - | ($308.0K) | - |
| Financing Cash Flow | $0 | - | - | - | $2.0K | - | - | - | $503.0K | - |
| CapEx | $0 | - | - | - | $5.0K | - | - | - | $308.0K | - |
| Free Cash Flow | ($3.37M) | - | - | - | ($14.91M) | - | - | - | ($12.13M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.61 | - | - | - | 0.76 | - | - | - | 0.78 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.0% | - | -13.3% | -16.3% | -13.8% | - | -4.3% | -9.1% | -7.8% | - |
| Return on equity | -8.3% | - | -17.2% | -20.6% | -17.0% | - | -5.1% | -10.8% | -9.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.05 | 7.77 | 8.04 | 7.89 | 9.18 | 8.03 | 8.93 | 8.46 | 11.15 | 12.45 |
| Quick ratio | 6.05 | 7.77 | 8.04 | 7.89 | 9.18 | 8.03 | 8.93 | 8.46 | 11.15 | 12.45 |
| Cash ratio | 5.49 | 7.03 | 6.88 | 6.78 | 8.28 | 7.07 | 7.04 | 7.55 | 10.13 | 11.28 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -467.3x | - | -1158.9x | -1943.7x | -1716.7x | - | -551.8x | -1306.1x | -1409.5x | - |
| Equity multiplier | 1.39 | 1.32 | 1.29 | 1.27 | 1.23 | 1.23 | 1.18 | 1.19 | 1.16 | 1.15 |
| Liabilities / Assets | 0.28 | 0.24 | 0.23 | 0.21 | 0.19 | 0.19 | 0.15 | 0.16 | 0.14 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | -100.0% | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 70.5% | - | -60.6% | -27.6% | -21.8% | - | 41.8% | 30.6% | 21.3% | - |
| Net income growth (YoY) | 71.8% | - | -79.5% | -24.8% | -26.9% | - | 42.3% | 28.9% | 14.8% | - |
| EPS growth (YoY) | 71.4% | - | -71.4% | -20.9% | -22.5% | - | 43.2% | 30.6% | 16.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 77.4% | - | - | - | -22.9% | - | - | - | -113.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -42.5% | -42.9% | -47.0% | -34.6% | -32.8% | -30.4% | -18.5% | -27.9% | -26.3% | -23.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$14.97M totalLicense$14.97M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vaccitech plc against the 5 most active filers in the same SIC group.